Finance

Molecular Partners to cut workforce by a quarter

Published by Global Banking & Finance Review

Posted on June 10, 2025

1 min read

· Last updated: January 23, 2026

Add as preferred source on Google
Molecular Partners to cut workforce by a quarter
Global Banking & Finance Awards 2026 — Call for Entries

ZURICH (Reuters) -Swiss biotech firm Molecular Partners said on Tuesday that it plans to reduce its workforce by up to 40 positions, or around 24%, as part of a strategic review to boost operational

Molecular Partners to cut workforce by a quarter

ZURICH (Reuters) -Swiss biotech firm Molecular Partners said on Tuesday that it plans to reduce its workforce by up to 40 positions, or around 24%, as part of a strategic review to boost operational efficiency and focus on key clinical assets.

The company, which develops DARPin protein therapeutics - a new type of engineered protein drugs - said the cuts aim to extend its cash runway into 2028, beyond earlier guidance of 2027.

CEO Patrick Amstutz said the move will support the advancement of pipeline candidates MP0533 and MP0712, with clinical data expected in the second half of 2025.

(Reporting by John Revill, Editing by Miranda Murray)

Key Takeaways

  • Molecular Partners to cut workforce by 24%.
  • The reduction aims to improve operational efficiency.
  • Focus will be on key clinical assets MP0533 and MP0712.
  • The move extends cash runway into 2028.
  • Clinical data expected in the second half of 2025.

Frequently Asked Questions

What percentage of the workforce is Molecular Partners cutting?
Molecular Partners plans to reduce its workforce by around 24%, which translates to up to 40 positions.
What is the purpose of the workforce reduction?
The cuts are part of a strategic review aimed at extending the company's cash runway into 2028.
What pipeline candidates will be supported by this decision?
The workforce reduction will support the advancement of pipeline candidates MP0533 and MP0712.
When is clinical data for the pipeline candidates expected?
Clinical data for the pipeline candidates MP0533 and MP0712 is expected in the second half of 2025.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category